➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Medtronic
Johnson and Johnson
Dow
McKinsey

Last Updated: October 28, 2020

DrugPatentWatch Database Preview

Details for Patent: 6,514,529

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,514,529 protect, and when does it expire?

Patent 6,514,529 protects ZYVOX and is included in one NDA.

Protection for ZYVOX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-eight patent family members in thirty-three countries.

Summary for Patent: 6,514,529
Title: Oxazolidinone tablet formulation
Abstract:The present invention provides a compressed tablet of an antibacterial oxazolidinone agent which provides high drug load and excellent bioavailability.
Inventor(s): Yamamoto; Ken (Portage, MI), Lin; Homer (Oak Park, CA)
Assignee: Pharmacia & Upjohn Company (Kalamazoo, MI)
Application Number:09/809,696
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,514,529
Patent Claim Types:
see list of patent claims
Dosage form; Use; Composition; Formulation;

Drugs Protected by US Patent 6,514,529

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pharmacia And Upjohn ZYVOX linezolid TABLET;ORAL 021130-001 Apr 18, 2000 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Pharmacia And Upjohn ZYVOX linezolid TABLET;ORAL 021130-002 Apr 18, 2000 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,514,529

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 033357   Start Trial
Austria 412413   Start Trial
Australia 2001243243   Start Trial
Australia 4324301   Start Trial
Bulgaria 107117   Start Trial
Brazil 0108846   Start Trial
Canada 2400118   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Dow
Harvard Business School
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.